...S.F. Yeo; Y.F. Chiew; C.P. Fung The in vitro activities of cefaclor, cefetamet, cefixime, cefotaxime and cefuroxime were determined against 150 isolates of Haemophilus influenzae . These included 50 ampicillin-susceptible, 50 β-lactamase-producing and 50 intrinsically ampicillin-resistant isolates...

...Milap C. Nahata; Veronika M. Kohlbrenner; William J. Barson Limited data are available about cefixime pharmacokinetics and cerebrospinal fluid (CSF) penetration in infants and young children. Ten patients with bacterial meningitis and 8 undergoing CSF shunt placement, aged 2-22 months (mean 9.5...

...A. Fietta; C. Merlini; Gialdroni Grassi The in vitro effects of cefixime and cefdinir (CI 983), two so-called third-generation oral cephalosporin derivatives, on human polymorphonuclear and mononuclear phagocyte functions (random migration and chemotaxis, specific and nonspecific phagocytosis...

...E. Yourassowsky; M.P. Van der Linden; F. Crokaert A new method of data presentation that takes into account the relationship between growth and killing rate was used to evaluate the comparative in vitro bactericidal activity of cefpodoxime, cefuroxime, cefixime and an amoxicillin/clavulanic acid...

...Sharon M. Smith; Robert H.K. Eng Cefixime is an orally absorbable cephalosporin with an extended spectrum of in vitro activity for gram-negative bacteria especially members of the Enterobacteriaceae . Gram-negative rod isolates collected over a three month period were tested against cefixime...

...Ashir Kumar; Kenneth J. Kelly In vitro activity of cefixime, an experimental oral third-generation cephalosporin and 7 other antimicrobials (ampicillin, augmentin, trimethoprim/sulfamethaxa-zole, cefamandole, cefotaxime, cefuroxime, and cefaclor) were determined for 150 isolates of Haemophilus...

..., at the end of treatment and 1 week after treatment, to determine the effect on the stool yeast concentration. Candida -colonized mice treated with cefepime, cefixime or ceftibuten had higher (however not significantly) counts of the yeast in their stools than control Candida -fed mice treated with saline...

...Endre Ludwig Cefixime is quickly establishing in Western countries as a potent broad-spectrum antibiotic with a variety of indications. A multinational, nonrandomized study in Central and Eastern Europe has confirmed the excellent efficacy of cefixime in both children and adults. In 45 children...

...Yoshimi Matsumoto The rising incidence of antibiotic resistance, including penicillin-resistant Streptococcus pneumoniae (PRSP), has become a great clinical problem in many countries. Cefixime, an orally active third-generation cephalosporin has broad and potent activity against various pathogens...

...Dieter Adam Third-generation cephalosporins in oral formulations have become an increasingly important first-line choice against common bacterial infections. Cefixime is one such agent, which possesses excellent efficacy against a broad spectrum of pathogens, including Haemophilus influenzae...

... put forward to explain this, including poor patient compliance and inactivation by beta-lactamase-producing oropharyngeal flora. Secondly, this has added to the demand for new agents to treat resistant streptococci. Cefixime, an orally active third-generation cephalosporin, has attracted considerable...

... was noted with cefixime, corresponding to an MIC of ≦4 µg/ml, at 99.2% (504 of 507). The results raise questions about the choice of antibiotics currently used in general practice, and suggest that cefixime may be a better first-line empiric treatment for noncomplicated UTIs. 1998 Copyright / Drug...

...-generation cephalosporin cefixime is a primary candidate for switch therapy owing to its very good efficacy and safety profile. Preliminary studies have shown excellent clinical outcomes with switch therapy to cefixime after 2–3 days for a variety of serious infections. Importantly, dramatic cost benefits...

...Joachim Lorenz The focus of a multicenter trial conducted in Germany was to investigate whether a 5-day short course of cefixime 400 mg was equivalent to a 10-day standard therapy of cefixime 400 mg in the treatment of acute exacerbation of chronic bronchitis (AECB). In the 167 patients who were...